Sandoz acquires Fougera for $1.5 billion

BASEL, Switzerland — Novartis' generics division has acquired Fougera Pharmaceuticals, the company said Wednesday.



Sandoz announced the acquisition of Melville, N.Y.-based Fougera for $1.525 billion in cash. Fougera specializes in generic dermatology drugs, and Sandoz said the acquisition would make it the world's largest company in the space.



"The addition of Fougera's leading portfolio further strengthens Sandoz's differentiated products strategy and improves our ability to help patients and customers around the world by providing easier access to high-quality, affordable dermatological medicines," Sandoz global head Jeff George said. "Fougera brings us valuable technical capabilities in the area of topical dermatological products, particularly in the development and manufacturing of semi-solid forms such as creams and ointments."



Fougera had sales of $429 million in 2011 and employs about 700 people at its two sites in New York, according to IMS Health.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.